GlassScriptPhysician profile
Steven P Ogden
NPI 1093080384
$6,218.97
in general payments reported to CMS, 2019-2025
41 companies · $860 in 2025
The $860 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $794 · 2021: $677 · 2022: $973 · 2023: $1,480 · 2024: $838 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,081 · Education: $96.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,080.62 |
| Education | $96.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $501.03 | 2019-2025 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $440.02 | 2019-2025 | Ofev, Jardiance, Tradjenta |
| Lilly USA, LLC | $423.18 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $422.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $408.04 | 2019-2025 | |
| Abbvie INC. | $401.06 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $394.14 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $369.16 | 2019-2024 | Austedo Xr, Austedo |
| Amgen INC. | $358.14 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $341.91 | 2019-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.95 | 2020-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $206.84 | 2020-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $184.88 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $163.00 | 2019-2025 | Spravato, Xarelto |
| Vanda Pharmaceuticals INC. | $141.48 | 2020-2023 | Hetlioz, Fanapt |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ogden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.